Assessment of causality and severity of various reported adverse drug reactions by different classes of anti-cancer drugs

Authors

  • Shaheena Rasool Department of Pharmacology, Government Medical College, Srinagar, Jammu and Kashmir, India
  • Masarat Nazeer Department of Pharmacology, Government Medical College, Srinagar, Jammu and Kashmir, India
  • Mehwish Majeed Department of Pharmacology, SKIMS, Soura, Srinagar, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20180665

Keywords:

Anti-cancer drugs, Chemotherapy, Hart wig and Siegel scale, WHO-UMC system

Abstract

Background: Chemotherapy involves highly complex regimens and hence accounts to high susceptibility towards Adverse Drug Reactions. All antineoplastic drugs have potential to cause one or more Adverse Drug Reactions which may vary from mild to severe form. So the aim of this study was to determine the prevalence of Adverse Drug Reactions in patients treated with chemotherapy.

Methods: After getting approval from the Institutional Ethical Committee, the prospective observational study was conducted in the Department of Pharmacology in association with Department of Radiation Oncology and Department of Medicine, Government Medical College, Srinagar between April 2015 to October 2016. All patients of either sex and any age receiving anti-cancer drugs in the inpatient department of radiation oncology were included. The mean age of the study population was 51 years and 53.9% of them were males and 46.1% of them were females. The WHO-UMC system was used for assessment of case programme and case reports. The severity of adverse drug reactions was determined by using modified Hart wig and Siegel scale.

Results: Most of the reported ADR’s were moderate to mild in severity according to modified Hart wig and Siegel scale. Most of the frequent ADR’s were certain followed by probable and possible according to WHO-UMC causality assessment.

Conclusions: Antineoplastic drugs have a narrow therapeutic index and the dosage needed to achieve a therapeutic response usually proves toxic to the body’s rapidly proliferating cells. Measures need to be put into place to reduce the physical, emotional and economic burden on the patient due to adverse drug reactions. Therefore, there is a need for vigilant ADR monitoring to decrease morbidity and mortality due to ADR’s which require further studies on large populations.

References

Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of prospective and retrospective studies. Bandolier Extra. 2002;2:1-16.

Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse reactions in hospitalized patients - A meta-analysis of prospective studies. JAMA. 1998;279:1200-5.

Ali I, Wani WA, Saleem K. Cancer scenario in India with future perspectives. Cancer Therapy. 2011;8:56-70.

Wynder, Ernst I, Lirio S. Covey, Kiyohikomabuchi. Current smoking habits by selected background variables: their effect on future disease trends. American Journal of Epidemiology. 1974;100.3:168-77.

Chabner BA, Amrein PC, Bruken BJ. Antineoplastic agents. In: Bruntan LL, Lazo JS, Parker KL, editors. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 11th Ed. USA: McGraw Hill Companies. Inc.; 2006:1315.

Muller T. Typical medication errors in oncology: Analysis and prevention strategies. Onkologie. 2003;26:539-44.

Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer. 2004;12:626-33.

WHO. International drug monitoring - the role of the national centers. Tech Rep ser WHO, No. 1972;498.

Hartwig SC, Seigel J, Schneider PJ. Preventibility and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm. 1992;49(9):2229-32.

Classen D, Ptestotnik SL, Scott Evans R. Adverse drug events in hospitalized patients: excess length of stay, extra costs and attributable motility. JAMA. 1997;277:301-06.

Kirthi C, Azra A, Reddy M, Syed AA, Yerramilli A, Sharma S. A study on the adverse effects of anticancer drugs in an oncology center of a tertiary care hospital. Int J Pharm Pharm Sci. 2014;6(2):580-3.

Goyal YN, Solanki KC, Mistry RA, Joshi ND, Singh AP, Gajera MV. Pattern of Adverse Drug Reactions Due to Cancer Chemotherapy in Tertiary Care Teaching Hospital in Gujarat. International Journal of Scientific Research. 2014;3(1):333-5.

Prasad A, Datta PP, Bhattacharya J, Pattanayak C, Chauhan AS, Panda P. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Eastern India. J Pharmacovigilance. 2013 Feb 8;1(2):107.

Downloads

Published

2018-02-22

How to Cite

Rasool, S., Nazeer, M., & Majeed, M. (2018). Assessment of causality and severity of various reported adverse drug reactions by different classes of anti-cancer drugs. International Journal of Basic & Clinical Pharmacology, 7(3), 503–510. https://doi.org/10.18203/2319-2003.ijbcp20180665

Issue

Section

Original Research Articles